We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% for Ocular Surface Disease in Glaucoma

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2011 by Mahidol University.
Recruitment status was:  Recruiting
ClinicalTrials.gov Identifier:
First Posted: January 27, 2011
Last Update Posted: January 27, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Mahidol University
To study effect of hydroxypropylmethylcellulose 0.3% and sodium hyaluronate 0.18% in the treatment of ocular surface disease in glaucoma patients.

Condition Intervention
Ocular Surface Disease Glaucoma Drug: hydroxypropylmethylcellulose Drug: sodium hyaluronate

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effect of Hydroxypropylmethylcellulose 0.3% and Sodium Hyaluronate 0.18% in the Treatment of Ocular Surface Disease in Glaucoma Patients

Resource links provided by NLM:

Further study details as provided by Mahidol University:

Primary Outcome Measures:
  • Ocular surface index score [ Time Frame: 1 month ]

Secondary Outcome Measures:
  • Eye lid inflammation, corneal staining score, tear break up time and tear volume [ Time Frame: 1 month ]

Estimated Enrollment: 120
Study Start Date: January 2011
Estimated Study Completion Date: February 2012
Estimated Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TearA Drug: hydroxypropylmethylcellulose
TearA: QID to every 2 hous , 1-2 drops per each time , duration 1 month
Experimental: TearB Drug: sodium hyaluronate
QID to every 2 hous, 1-2 drops per each time, duration 1 month


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • OSDI > or equal 20 and eye lid inflammation , meibomian gland inflammation,conjunctival injection,follicle at tarsus , positive corneal staining , tear break up time less than 8 seconds , tear volume less than 5.5 mm.

Exclusion Criteria:

  • Age below 18 yo
  • Active infectious corneal disease
  • Post penetrating keratoplasty or glaucoma drainage device
  • Known allergy to medication
  • Lactation , Pregnant
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01284439

Contact: AssocProf Pinnita Tanthuvanit 02-4198036

Department of Ophthalmology , Siriraj Hospital Recruiting
Bangkok, Thailand
Principal Investigator: Assoc Prof Pinnita Tanthuvanit         
Sponsors and Collaborators
Mahidol University
Principal Investigator: AssocProf Pinnita Tanthuvanit, MD Mahidol University
  More Information

Responsible Party: AssocProf Pinnita Tanthuvanit, Department of Ophthalmology
ClinicalTrials.gov Identifier: NCT01284439     History of Changes
Other Study ID Numbers: 655/2553(EC4)
First Submitted: January 25, 2011
First Posted: January 27, 2011
Last Update Posted: January 27, 2011
Last Verified: January 2011

Additional relevant MeSH terms:
Ocular Hypertension
Eye Diseases
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Protective Agents